

ESMO PRECEPTORSHIP PROGRAMME BREAST CANCER

Multidisciplinary management, standards of care, therapeutic targets
and future perspectives

Lima, Peru
9-10 April 2025

CO-CHAIRS

Carlos H. Barrios, Brazil
Nadia Harbeck, Germany

SPEAKERS

Sergio Cervera, Colombia
Giuseppe Curigliano, Italy
Evandro De Azambuja, Belgium
Franco Doimi, Peru
Sandra X. Franco, Colombia
Pablo Mando, Argentina
Silvia Neciosup, Peru
Nina Ditsch, Germany
Arthur A. Rosa, Brazil

LEARNING OBJECTIVES

- To enable the interdisciplinary discussion and collaboration in the care of patients with breast cancer
- To understand subtype-specific breast cancer management
- To improve the understanding of current radiological and pathological diagnostics
- To learn about the latest developments in neoadjuvant and adjuvant therapies
- To gain insight into the role of complementary and lifestyle interventions and supportive care
- To review approaches to the care of patients with advanced breast cancer
- To learn about specific needs of young patients with breast cancer

ACCREDITATION

The programme of this event will be accredited with **XX ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4 - 6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org



Wednesday, 9 April 2025

14:30-14:35 5'	Opening remarks	Carlos H. Barrios, BR Nadia Harbeck, DE
-------------------	-----------------	--

14:35-16:20 105'	SESSION 1 Special situations	Chair: Nadia Harbeck, DE
30'	Lifestyle, complementary and alternative medicine	Silvia Neciosup, PE
15'	Q&A	All
20'	Young women: Genetics, counselling and therapeutic consequences	Nina Ditsch, DE
10'	Q&A	All
20'	Young women: Special issues (pregnancy, fertility, etc.)	Nina Ditsch, DE
10'	Q&A	All

16:20-16:50	Coffee break	
-------------	--------------	--

16:50-18:50 120'	SESSION 2 Breast imaging and loco-regional treatment in Early Breast Cancer (EBC)	Chair: Nadia Harbeck, DE
20'	Breast Cancer in Latin America	Carlos H. Barrios, BR
10'	Q&A	All
20'	Update on breast pathology: What do we need to know in the clinic? (e.g. Liquid Bx, Molecular Tumor Board, HER2-low, triple negative histologies,...)	Franco Doimi, PE
10'	Q&A	All
20'	Contemporary breast and axillary surgery	Sergio Cervera, CO
10'	Q&A	All
20'	Contemporary indications for radiation therapy	Arthur A. Rosa, BR
10'	Q&A	All

20:00-22:00	Networking dinner	
-------------	-------------------	--

Thursday, 10 April 2025

09:00-10:30 90'	SESSION 3 Participants clinical case discussion	Chair: Carlos H. Barrios, BR
90'	Participants clinical case discussion (6x15')	Faculty
10:30-11:00	Coffee break	
11:00-12:35 95'	SESSION 4 Systemic therapy in Early Breast Cancer (EBC)	Chair: Carlos H. Barrios, BR
25'	Luminal	Nadia Harbeck, DE
10'	Q&A	All
20'	Triple negative	Evandro de Azambuja, BE
10'	Q&A	All
20'	HER2 positive	Silvia Neciosup, PE
10'	Q&A	All
12:35-13:35	Lunch	
13:35-14:05 30'	SESSION 5 Loco-regional treatment in Metastatic Breast Cancer	Chair: Nadia Harbeck, DE
20'	Barriers to access to optimal breast cancer care in Latin America	Pablo Mando, AR
10'	Q&A	All
14:05-15:45 100'	SESSION 6 Systemic therapy in Metastatic Breast Cancer	Chair: Carlos H. Barrios, BR
30'	Advanced luminal breast cancer (incl. HER2-low)	Giuseppe Curigliano, IT
10'	Q&A	All
20'	Advanced triple negative breast cancer	Sandra X. Franco, CO
10'	Q&A	All
20'	Advanced HER2 positive breast cancer	Giuseppe Curigliano, IT
10'	Q&A	All
15:45-16:15	Coffee break	
16:15-17:45 90'	SESSION 7 Participants clinical case discussion	Chair: Nadia Harbeck, DE
90'	Participants clinical case discussion (6x15')	Faculty
17:45-18:00 15'	Closing remarks	Carlos H. Barrios, BR Nadia Harbeck, DE

Note: Each 15-minute slot for clinical case discussion includes a 7' case presentation and an 8' Q&A / panel discussion